Integrated Biomarkers & Omics in Heart Failure: Risk Stratification, Proteomics, and Advanced Therapy

This session brings together clinical and translational leaders to demonstrate how targeted biomarkers and multi-omic strategies can prevent progression, personalize therapy, and guide advanced heart-failure care. Speakers will review multimarker risk assessment for early remodeling and cardiotoxicity surveillance; biomarker-guided cardiorenal optimization using aldosterone/renin ratios, cystatin C eGFR, and UACR; practical implementation of serial and point-of-care proteomics to refine prognosis and monitor treatment response; and application of multi-omics with imaging in the advanced heart failure population.

Attendees will gain actionable guidance on test selection, sampling interval, interpretation, and pragmatic workflows to employ these cutting-edge technologies to deliver precision-medicine focused care. 

Learning Objectives

• Integrate cardiovascular and kidney biomarkers into risk stratification and precision-guided management strategies in patients with established heart failure or those at risk for its development.
• Describe how serial and point-of-care proteomic measurements can be applied in clinical workflows to improve prognosis, detect early decompensation, and guide treatment selection and monitoring.
• Apply current multi-omic tools and integrated imaging/biomarker strategies to noninvasively surveil heart transplant rejection, stratify risk, and recovery, in patients with LVADs